A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice

Translational Psychiatry, Journal Year: 2022, Volume and Issue: 12(1)

Published: Sept. 28, 2022

(R,S)-ketamine is known to elicit persistent prophylactic effects in rodent models of depression. However, the precise molecular mechanisms underlying its action remain elusive. Using RNA-sequencing analysis, we searched for novel target(s) that contribute (R)-ketamine, a more potent enantiomer chronic restraint stress (CRS) model. Pretreatment with (R)-ketamine (10 mg/kg, 1 day before CRS) significantly ameliorated body weight loss, increased immobility time forced swimming test, and decreased sucrose preference test CRS-exposed mice. analysis prefrontal cortex (PFC) revealed several miRNAs such as miR-132-5p might sustained (R)-ketamine. Methyl CpG binding protein 2 (MeCP2) regulate brain-derived neurotrophic factor (BDNF) expression. Quantitative RT-PCR confirmed attenuated altered expression regulated genes (Bdnf, Mecp2, Tgfb1, Tgfbr2) PFC Furthermore, BDNF, MeCP2, TGF-β1 (transforming growth β1), synaptic proteins (PSD-95, GluA1) Administration agomiR-132-5p Bdnf Tgfb1 PFC, resulting depression-like behaviors. In contrast, administration antagomiR-132-5p blocked mice, antidepressant-like effects. conclusion, our data show role phenotypes CRS model

Language: Английский

---

Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism

Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 49(1), P. 96 - 103

Published: July 21, 2023

Abstract The clinical investigation of psychedelic medicines has blossomed over the last 5 years. Data from a Phase 3 industry trial and multicenter 2 trial, in addition to multiple early phase investigator-initiated trials, have now been published peer-reviewed journals. This narrative review summarizes both recent data current trials that are being conducted with various classes “psyche-manifesting” substances, which may prove beneficial treatment broad range conditions. Methodological considerations, unique challenges, next steps for research discussed keeping uniquely “experiential” nature these therapies.

Language: Английский

---

Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms

European Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 75, P. 1 - 14

Published: June 21, 2023

Eating disorders are serious illnesses showing high rates of mortality and comorbidity with other mental health problems. Psychedelic-assisted therapy has recently shown potential in the treatment several common comorbidities eating disorders, including mood post-traumatic stress disorder, substance use disorders. The theorized therapeutic mechanisms psychedelic-assisted suggest that it could be beneficial as well. In this review, we summarize preliminary data on efficacy people anorexia nervosa, bulimia binge which include studies case reports ketamine, MDMA, psilocybin, ayahuasca. We then discuss these three both general those relatively specific to find evidence may effective nervosa very little available disorder. Regarding mechanisms, able improve beliefs about body image, normalize reward processing, promote cognitive flexibility, facilitate trauma processing. Just importantly, appears factors relevant many their comorbidities. Lastly, safety concerns associated treatments present recommendations for future research.

Language: Английский

---

A pilot randomized controlled trial of ketamine in Borderline Personality Disorder

Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 48(7), P. 991 - 999

Published: Feb. 17, 2023

Language: Английский

---

Effectiveness of Ketamine for the Treatment of Post-Traumatic Stress Disorder - A Systematic Review and Meta-Analysis.

PubMed, Journal Year: 2024, Volume and Issue: 21(1), P. 22 - 31

Published: Feb. 1, 2024

Post-traumatic stress disorder (PTSD) is an enduring condition characterized by a chronic course and impairments across several areas. Despite its significance, treatment options remain limited, remission rates are often low. Ketamine has demonstrated antidepressant properties appears to be promising agent in the management of PTSD.

Language: Английский

---